Informal Collaborations - Investigators interested in scientific collaborations should contact the STB scientific staff directly.
Cooperative Research and Development Agreements (CRADAs) - Research aimed at commercialization of Government inventions or collaborative research with potential commercial applications may be pursued through CRADAs
List of current or pending STB CRADAs:
- Preclinical and Non-Clinical Studies of TopoTarget's Proprietary Histone Deacetylase (HDAC) Inhibitors as Anti-Cancer Agents. Collaborator: TopoTarget, Copenhagen, Denmark.
List of completed STB CRADAs:
- Novel Small Molecule Inhibitors of the Hypoxic Signaling Pathway from MerLion's Natural Products Collections. Collaborator is MerLion Pharmaceuticals, Singapore.
- 2-Methoxyestradiol and Analogs as Inhibitors of Hypoxia Inducible Factor-1. Collaborator is Entremed.
- Evaluation of Topoisomerase I Inhibitors as Antitumor Inhibitors of Hypoxia Inducible Factor 1 (HIF-1). Collaborator is Sigma Tau Pharmaceuticals, Italy; this M-CRADA has recently expired however.
Submitting Compounds for Screening
- We have rabbit polyclonal antibodies for detecting and characterizing the two fusion proteins which occur in alveolar soft part sarcoma (ASPS).
The Drug Discovery and Development Seminar Series - Since 1999, the Branch has hosted numerous experts from academia and private industry in the field of drug discovery and development where they present their work to an open audience at NCI-Frederick. For more information on the seminar series, contact Ms. Pam Young.